Molecular and Clinical Spectrum of Epilepsy-Dyskinesia Syndromes: A Cross-Sectional Study of 609 Patients

Epilepsy-dyskinesia syndromes (EDS) represent a clinically complex group of neurogenetic disorders defined by overlapping seizure activity and movement disorders

By
October 19, 2026
2 min

Phoenix Children's Medical Connection

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Molecular and Clinical Spectrum of Epilepsy-Dyskinesia Syndromes
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	609 pediatric patients with childhood-onset movement disorders; pathogenic variants were identified across 74 of 105 predefined genes.
Care Setting	Multinational cross-sectional study conducted at more than 30 centers in 25 countries, characterizing clinical features and treatment responses.

Key Highlights

Pathogenic variants were identified in 74 of 105 predefined genes; 12 genes accounted for two-thirds of cases.
Dystonia, stereotypies, and ataxia were the most common movement disorders, and most patients had mixed movement disorder presentations.
Epilepsy was present in approximately two-thirds of patients.
Developmental outcomes and pharmacologic responses varied by genetic etiology and pathway involvement.
The study reported carbamazepine responsiveness in PRRT2-related disease and worsening motor symptoms with levodopa/carbidopa in patients with GNAO1 or MECP2 variants.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

609 pediatric patients with childhood-onset movement disorders and pathogenic variants across 74 of 105 predefined genes.

Pharmacologic responses varied by genetic etiology and pathway involvement. The study confirmed carbamazepine responsiveness in PRRT2-related disease and reported motor symptom worsening with levodopa/carbidopa in GNAO1 and MECP2 variants.